November 10, 2022 Gain Therapeutics, Inc. Reports Third Quarter 2022 Financial Results and Business Update Read More
September 26, 2022 Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons Read More
September 20, 2022 Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer Read More
September 19, 2022 Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease Read More
September 6, 2022 Gain Therapeutics To Participate At The H.C. Wainwright 24th Annual Global Investment Conference Read More
August 8, 2022 Gain Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Business Update Read More
May 18, 2022 Gain Therapeutics to Participate at the H.C. Wainwright Global Investment Conference Read More
May 16, 2022 Gain Therapeutics, Inc. Reports First Quarter 2022 Financial Results and Business Update Read More
May 11, 2022 Gain Therapeutics Presents Positive Preclinical Data On Its Gaucher Disease Program at IWGGD Symposium Read More
May 6, 2022 Gain Therapeutics Presents Positive Preclinical Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at XXVII IAPRD World Congress Read More
April 26, 2022 Gain Therapeutics to Participate in the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference Read More
April 12, 2022 Gain Therapeutics Presents Positive Data on its Small Molecule Lead Compound in GBA1 Parkinson’s Disease at the 2022 Synuclein Meeting Read More
March 29, 2022 Gain Therapeutics Presents Additional Confirmatory Data on its Gaucher Disease Program at the 2022 Glycolipid and Sphingolipid Biology Gordon Research Conference Read More
March 24, 2022 Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update Read More
March 15, 2022 Gain Therapeutics Presents Positive Data on its Structurally Targeted Allosteric Regulators in both Parkinson’s and Alzheimer’s Disease at the AD/PD 2022 Conference Read More
March 1, 2022 Gain Therapeutics Announces Participation in Upcoming Investor and Scientific Conferences Read More
February 8, 2022 Gain Therapeutics Presents Preclinical Data on its Structurally Targeted Allosteric Regulators in GBA1 Gaucher Disease at the WORLDSymposium 2022 Read More
February 4, 2022 Gain Therapeutics Outlines Key Objectives for 2022 Following its Inaugural R&D Day Read More
January 31, 2022 Gain Therapeutics Announces Additional Details on its February 4th Virtual R&D Day Read More
January 18, 2022 Gain Therapeutics Announces R&D Day Event and Participation in Upcoming Conferences Read More
January 6, 2022 Gain Therapeutics to Participate at the H.C. Wainwright Bioconnect Virtual Conference Read More
